Cancer Advisor

Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the preclin...

Executive Summary Cancer is increasingly recognized not only as a genetic disease but also as a metabolic disease . While genetic mutations drive tumor initiation and progression, metabolic reprogramming provides the fuel that allows cancer cells to survive, adapt, evade the immune system, and resist treatment. Over the past decade, metabolic oncology has evolved from a niche research field into one of the most promising frontiers in cancer treatment. However, many discussions remain polarized. Some portray cancer as purely a metabolic disease, while others dismiss metabolic interventions altogether. The scientific evidence suggests a more nuanced reality: Cancer is simultaneously a genetic, metabolic, immunological, and ecological disease. Successful treatment often requires addressing all of these dimensions systematically. This article prese...

Introduction: Why This Debate Matters Right Now The metabolic theory of cancer is exploding in popularity. Professor Tom Seyfried has become a household name among patients seeking alternatives to conventional oncology, thanks to his groundbreaking book Cancer as a Metabolic Disease and the press-pulse strategy built around glucose and glutamine restriction. But in May 2026, Jane McLelland —bestselling author of How to Starve Cancer and a stage 4 cancer survivor who reversed her own disease—published an interesting Substack titled “ Beyond Warburg: What Tom Seyfried Gets Right — And the Blind Spot That Could Cost Your Patient. ” This isn’t a takedown. It’s a respectful, evidence-based extension that could save lives by highlighting a critical limitation in the “keto-for-everyone” approach. If you’re exploring ketogenic diet cancer protocols, repurposed drugs, or metabolic therapies, this article breaks it all down with actionable insights into the metabolic theory of canc...

Quick Answer Dr. Thomas Seyfried , a biologist at Boston College, argues that cancer is primarily a mitochondrial metabolic disease rather than a genetic one. His core treatment framework — the Press-Pulse protocol — pairs a therapeutic ketogenic diet that restricts glucose and glutamine (the "press") with pulsed adjuncts like glutaminase-inhibiting drugs, hyperbaric oxygen, or fasting (the "pulse"). Mechanistic and preclinical evidence is strong; human evidence is a mix of promising case reports and small, mostly inconclusive trials — including a 2026 randomized pancreatic cancer trial that showed a survival trend without reaching statistical significance. Most integrative oncologists treat metabolic therapy as a physician-supervised adjunct to, not a replacement for, standard cancer care. In This Guide Who Is Thomas Seyfried? The Case Against Standard-of-Care Statistics Diet and Cancer: Why Food Isn't Neutral Cutting Off Cancer's Fu...